Phase I news from FierceBiotech
NewsBMS inks $710M development deal with PDL
Bristol-Myers Squibb is paying $30 million upfront in a licensing deal for PDL BioPharma's... Read more...
BioVascular raises $10.87M
With the help of lead investor BB Biotech Ventures, BioVascular rounded up $10.87 million in series C financing. The San Diego, CA-based company plans on using the money to complete clinical trials... Read more...
ALSO NOTED: Tacere gains Pfizer deal; InterMune reports positive hep C results; ArQule CEO resigns; and much more...
> Tacere Therapeutics has inked a development deal with Pfizer for its preclinical hepatitis C drug. The deal is worth up to $145 million in potential milestones and Pfizer is paying an... Read more...
Novacea slows down development program for AQ4N
Novacea, which is burning through $17 million to $19 million this year, says it will scale back on the development of AQ4N, shelving a clinical trial in acute lymphoblastic leukemia and delaying a... Read more...
Medarex shares dive after a cancer trial failure
Shares of Medarex took a dive in after-hours trading after the biotech announced that the cancer drug ipilimumab--
Astellas inks $537M deal for Agensys
Japan's Astellas has forged a deal to buy Santa Monica, CA-based
Synta outlines cash flow from Glaxo pact
Synta Pharmaceuticals' new, $1 billion pact with GlaxoSmithKline for the cancer drug elesclomol (code named... Read more...
Memory's Alzheimer's drug aces Phase II
Memory Pharmaceuticals has announced a positive Phase II roof-of-concept trial of MEM 3454 in 80 patients with Alzheimer's disease over an eight week treatment period. The primary endpoint of the... Read more...
ALSO NOTED: Renovis' CEO steps down; Isis gains $5M milestone; and much more...
> Chutes & Ladders: Corey Goodman is stepping down as CEO of Renovis as the company completes its
Roche halts Phase I trial
Roche has halted a trial of MAXY-alpha, also known as R7025, due to an unanticipated reduction of the pharmacodynamic and pharmacokinetic effects in patients who received the drug. Roche and... Read more...
| Press ReleasesOrexigen Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)Orexigen Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release Used in Contrave PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: Read more >> AVEO Pharmaceuticals Initiates First Clinical Trial of Novel HGF Antagonist in Patients with Advanced Solid Tumors and LymphomasAVEO Pharmaceuticals Initiates First Clinical Trial of Novel HGF Antagonist in Patients with Advanced Solid Tumors and Lymphomas SCH900105 (AV-299) Marks First of Several Monoclonal Antibodies from Read more >> RegeneRx Enrolls First Subject in RGN-352 Phase IB Clinical TrialRegeneRx Enrolls First Subject in RGN-352 Phase IB Clinical Trial BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has enrolled Read more >> Gene therapy for chronic pain gets first test in peopleGene therapy for chronic pain gets first test in people U-M Phase 1 trial will test therapy in cancer patients with intractable pain ANN ARBOR, Mich. -This week, University of Michigan scientists Read more >> Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine ProgramNovavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Read more >> |
Get more Phase I coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
